Brainstorm Cell Therapeutics (BCLI) Stock Hits One-Year High Today

NEW YORK ( TheStreet) -- Shares of Brainstorm Cell Therapeutics (BCLI) surged more than 75% to a 52-week high of $8.47 on Fridayahead of the biotech company's data release on Monday.

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

Exclusive Report: Jim Cramer's Best Stocks for 2015

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

View original post here:
Brainstorm Cell Therapeutics (BCLI) Stock Hits One-Year High Today

Neuralstem (CUR) Stock Rises Today as Brainstorm Cell Therapeutics Soars

NEW YORK (TheStreet) -- Shares ofNeuralstem (CUR) continue to rise, up 6.25% to $2.89, in morning trading Friday in sympathy with peer company Brainstorm Cell Therapeutics (BCLI) , which touched a one-year high on Friday.

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

The rest is here:
Neuralstem (CUR) Stock Rises Today as Brainstorm Cell Therapeutics Soars

Stem Cell Therapy Fixes Post-Surgical Airway Abnormality

By Steven Reinberg HealthDay Reporter

WEDNESDAY, Dec. 31, 2014 (HealthDay News) -- Using stem cells derived from a patient's own bone marrow, researchers have repaired a fistula -- a potentially fatal tissue abnormality -- in the man's lower airway.

"This is another interesting new therapeutic approach for stem cells," said lead researcher Dr. Francesco Petrella, deputy director of thoracic surgery at the European Institute of Oncology in Milan, Italy.

The patient, a 42-year-old firefighter, developed the fistula after surgeons removed a lung as part of treatment for mesothelioma cancer. A fistula is abnormal tissue connecting an organ, blood vessel or intestine to another structure. In this case, the fistula developed between the lower airway and the tissue that surrounds the lungs.

"Our clinical experience supports the idea that stem cells could be effectively used to close some tissue defects developing after very complex surgical procedures, thus restoring a functioning airway," Petrella said.

A fistula that develops after chest surgery is serious and even deadly, Petrella said. Current treatments involve removing ribs and taking medications for months or years, he explained.

"Less invasive approaches like endoscopic glue injections have only poor results, so our proposed techniques could improve quality of life in these patients," Petrella said.

Sixty days after stem cell therapy, the firefighter's fistula was healed, the researchers said. The hole seen before stem cell therapy was no longer visible, having been replaced by new tissue created by the stem cell implant, they explained.

Some people are born with a fistula. Other causes of fistulas include complications from surgery, injury, infection and diseases, such as Crohn's disease or ulcerative colitis.

Petrella believes that this same stem cell technique could be used to treat fistulas that develop elsewhere in the body.

The rest is here:
Stem Cell Therapy Fixes Post-Surgical Airway Abnormality

Margot Martini's story can save lives with new charity

A charity in memory of inspirational toddler Margot Martini is being set up by her family with the aim of getting more than one million extra people to sign up to the UK stem cell register.

The Team Margot Foundation has the goal to get more than 1.5 million extra potential bone marrow donors to take the total to 2.5 million.

The foundation will also raise money and support the work of five charities - Great Ormond Street Hospital Childrens Charity, Delete Blood Cancer UK, Anthony Nolan, Shooting Stars Chase, and Momentum.

Two-year-old Margot died in October from two rare types of leukaemia following a worldwide search for a bone marrow donor.

Margot's parents, Vicki, originally from Essington, and Yaser, went public in their search for a bone marrow donor to help save their daughter's life.

Speaking exclusively to the Express & Star, Margot's father Yaser outlined plans for 2015 which will see Team Margot in full swing over the next 12 months.

They include, establishing the Team Margot Foundation to support the work of charities close to their heart, holding the first annual international Team Margot Stem Cell and Bone Marrow Awareness Day, supporting bone marrow donor registration events across the country, and a 40-day trek across the ice caps of Greenland, named Expedition Margot.

"We see this as Margot's legacy - and we want that to continue for the sake of others," said Mr Martini.

Margot's mother Vicki, 39, grew up in Essington, Staffordshire, and has marked her first Christmas without her daughter with Yaser, 44, and sons Oscar, seven, and Rufus, six.

Now they want 2015 to be the breakthrough year so no family has to suffer the anguish they did to find a matching bone marrow donor.

Visit link:
Margot Martini's story can save lives with new charity

'Bad Luck' of Random Mutations Plays Predominant Role in Cancer, Study Shows

Released: 30-Dec-2014 1:50 PM EST Embargo expired: 1-Jan-2015 2:00 PM EST Source Newsroom: Johns Hopkins Medicine Contact Information

Available for logged-in reporters only

Newswise Scientists from the Johns Hopkins Kimmel Cancer Center have created a statistical model that measures the proportion of cancer incidence, across many tissue types, caused mainly by random mutations that occur when stem cells divide. By their measure, two-thirds of adult cancer incidence across tissues can be explained primarily by bad luck, when these random mutations occur in genes that can drive cancer growth, while the remaining third are due to environmental factors and inherited genes.

All cancers are caused by a combination of bad luck, the environment and heredity, and weve created a model that may help quantify how much of these three factors contribute to cancer development, says Bert Vogelstein, M.D., the Clayton Professor of Oncology at the Johns Hopkins University School of Medicine, co-director of the Ludwig Center at Johns Hopkins and an investigator at the Howard Hughes Medical Institute.

Cancer-free longevity in people exposed to cancer-causing agents, such as tobacco, is often attributed to their good genes, but the truth is that most of them simply had good luck, adds Vogelstein, who cautions that poor lifestyles can add to the bad luck factor in the development of cancer.

The implications of their model range from altering public perception about cancer risk factors to the funding of cancer research, they say. If two-thirds of cancer incidence across tissues is explained by random DNA mutations that occur when stem cells divide, then changing our lifestyle and habits will be a huge help in preventing certain cancers, but this may not be as effective for a variety of others, says biomathematician Cristian Tomasetti, Ph.D., an assistant professor of oncology at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health. We should focus more resources on finding ways to detect such cancers at early, curable stages, he adds.

In a report on the statistical findings, published Jan. 2 in Science, Tomasetti and Vogelstein say they came to their conclusions by searching the scientific literature for information on the cumulative total number of divisions of stem cells among 31 tissue types during an average individuals lifetime. Stem cells self-renew, thus repopulating cells that die off in a specific organ.

It was well-known, Vogelstein notes, that cancer arises when tissue-specific stem cells make random mistakes, or mutations, when one chemical letter in DNA is incorrectly swapped for another during the replication process in cell division. The more these mutations accumulate, the higher the risk that cells will grow unchecked, a hallmark of cancer. The actual contribution of these random mistakes to cancer incidence, in comparison to the contribution of hereditary or environmental factors, was not previously known, says Vogelstein.

To sort out the role of such random mutations in cancer risk, the Johns Hopkins scientists charted the number of stem cell divisions in 31 tissues and compared these rates with the lifetime risks of cancer in the same tissues among Americans. From this so-called data scatterplot, Tomasetti and Vogelstein determined the correlation between the total number of stem cell divisions and cancer risk to be 0.804. Mathematically, the closer this value is to one, the more stem cell divisions and cancer risk are correlated.

Our study shows, in general, that a change in the number of stem cell divisions in a tissue type is highly correlated with a change in the incidence of cancer in that same tissue, says Vogelstein. One example, he says, is in colon tissue, which undergoes four times more stem cell divisions than small intestine tissue in humans. Likewise, colon cancer is much more prevalent than small intestinal cancer.

More here:
'Bad Luck' of Random Mutations Plays Predominant Role in Cancer, Study Shows

Two-thirds of cancer cases are "bad luck," study says

Chuck Bednar for redOrbit.com Your Universe Online

Two-thirds of all adult cancer cases are primarily the result of bad luck, according to the authors of a new study appearing in Fridays edition of the journal Science.

Dr. Bert Vogelstein, the Clayton Professor of Oncology at the Johns Hopkins University School of Medicine, and Dr. Cristian Tomasetti, an assistant professor of oncology at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health, developed a statistical model that measured the proportion of cancer incidence across many different tissue types.

They found that two-thirds of adult cancer incidence across tissues occur when the random mutations that take place during stem cell division drive cancer through, while the remaining one-third of cases are the result of environmental factors and inherited genes.

All cancers are caused by a combination of bad luck, the environment and heredity, and weve created a model that may help quantify how much of these three factors contribute to cancer development, explained Dr. Vogelstein, who is also co-director of the Ludwig Center at Johns Hopkins and an investigator at the Howard Hughes Medical Institute.

Cancer-free longevity in people exposed to cancer-causing agents, such as tobacco, is often attributed to their good genes, but the truth is that most of them simply had good luck, he said, adding that that poor lifestyle choices can also contribute to this so-called bad luck factor.

The authors said that the implications of their model could alter the public perception about cancer risk factors, as well as impact the funding of research related to the disease.

If most cancer cases can be explained by random DNA mutations that occur as stem cells divide, explained Dr. Tomasetti, it means that lifestyle changes will be a tremendous help when it comes to preventing some forms of the disease, but will be less effective against other types.

As a result, the medical community should should focus more resources on finding ways to detect such cancers at early, curable stages, he added. He and Vogelstein said that they reached their conclusion by searching scientific literature for data on the cumulative number of total stem cell divisions among 31 tissue types that take place during a persons lifetime.

Stem cells renew themselves, repopulating cells that die off in specific organs, the researchers said. Cancer arises when tissue-specific stem cells experience mutations in which one chemical letter in DNA is erroneously swapped for another during the replication process.

Read more:
Two-thirds of cancer cases are "bad luck," study says

One Reason Neuralstem (CUR) Stock is Rising Today

NEW YORK (TheStreet) -- Shares of stem cell therapy developerNeuralstem (CUR) rose 4.62% to $2.72 on higher-than-average volume in afternoon trading Wednesday in sympathy with peer companyBrainstorm Cell Therapeutics (BCLI) .

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

Exclusive Report: Jim Cramers Best Stocks for 2015

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Read more:
One Reason Neuralstem (CUR) Stock is Rising Today

Stem cell study leads to potential new dementia treatment

The research involved creating human cells in a laboratory dish instead of relying on tests on mice. Photograph: corfield / Alamy/Alamy

Cells used to study dementia in a dish have led scientists to a potential new treatment strategy for an inherited form of the brain disease.

Defective stem cells grown in the lab revealed a signalling pathway linked to frontotemporal dementia (FTD), which accounts for about half of dementia cases before the age of 60.

Treatment with a drug that suppressed the pathway, known as Wnt, restored the ability of neurons affected by the disease to develop normally.

Prof Philip Van Damme, from the Leuven Research Institute for Neuroscience and Disease in Belgium, said: Our findings suggest that signalling events required for neurodevelopment may also play major roles in neurodegeneration.

Targeting such pathways, as for instance the Wnt pathway presented in this study, may result in the creation of novel therapeutic approaches for frontotemporal dementia.

Mutations in the progranulin (GRN) gene are commonly associated with FTD, which results in damage to the frontal and temporal lobes of the brain.

The fact that GRN mutations produced in mice do not display all the features of the human disorder has limited progress towards effective treatments for FTD.

Instead of relying on animal tests, the new research involved creating human cells in a laboratory dish.

The scientists reprogrammed skin cells from three dementia patients into induced pluripotent stem cells (iPSCs), immature cells that mimic stem cells taken from early-stage embryos.

See more here:
Stem cell study leads to potential new dementia treatment

Brainstorm Cell Therapeutics (BCLI) Stock Rises Ahead of ALS Treatment Trial Data Release

NEW YORK (TheStreet) -- Shares ofBrainstorm Cell Therapeutics (BCLI) soared 20.88% to $4.69 on higher-than-average volume in morning trading Wednesday ahead of the biotech company's data release on Monday.

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

Exclusive Report: Jim Cramers Best Stocks for 2015

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

View post:
Brainstorm Cell Therapeutics (BCLI) Stock Rises Ahead of ALS Treatment Trial Data Release

Patient stem cells used to make dementia-in-a-dish; help identify new treatment strategy

IMAGE:Induced pluripotent stem cells (iPSCs) derived from patients with frontotemporal dementia were genetically corrected and converted to cortical neurons. The green staining indicates the cortical marker CTIP2, the red stain... view more

Credit: Susanna Raitano/Stem Cell Reports 2014

Belgian researchers have identified a new strategy for treating an inherited form of dementia after attempting to turn stem cells derived from patients into the neurons most affected by the disease. In patient-derived stem cells carrying a mutation predisposing them to frontotemporal dementia, which accounts for about half of dementia cases before the age of 60, the scientists found a targetable defect that prevents normal neurodevelopment. These stem cells partially return to normal when the defect is corrected.

The study appears in the December 31st issue of Stem Cell Reports, the official journal of the International Society of Stem Cell Research published by Cell Press.

"Use of induced pluripotent stem cell (iPSC) technology"--which involves taking skin cells from patients and reprogramming them into embryonic-like stem cells capable of turning into other specific cell types relevant for studying a particular disease--"makes it possible to model dementias that affect people later in life," says senior study author Catherine Verfaillie of KU Leuven.

Frontotemporal disorders are the result of damage to neurons in parts of the brain called the frontal and temporal lobes, gradually leading to behavioral symptoms or language and emotional disorders. Mutations in a gene called progranulin (GRN) are commonly associated with frontotemporal dementia, but GRN mutations in mice do not mimic all the features of the human disorder, which has limited progress in the development of effective treatments.

"iPSC models can now be used to better understand dementia, and in particular frontotemporal dementia, and might lead to the development of drugs that can curtail or slow down the degeneration of cortical neurons," Verfaillie says.

Verfaillie and Philip Van Damme of the Leuven Research Institute for Neuroscience and Disease explore this approach in the Stem Cell Reports study by creating iPSCs from three patients carrying a GRN mutation. These immature cells were impaired at turning into mature, specialized cells called cortical neurons--the most affected cell type in frontotemporal dementia.

One of the top defective pathways in the iPSCs was the Wnt signaling pathway, which plays an important role in neuronal development. However, genetic correction or treatment with a compound that inhibits the Wnt signaling pathway restored the ability of the iPSCs to turn into cortical neurons. Taken together, the findings demonstrate that the GRN mutation causes the defect in cortical neuron formation by altering the Wnt signaling pathway.

"Our findings suggest that signaling events required for neurodevelopment may also play major roles in neurodegeneration," Van Damme says. "Targeting such pathways, as for instance the Wnt pathway presented in this study, may result in the creation of novel therapeutic approaches for frontotemporal dementia."

Go here to see the original:
Patient stem cells used to make dementia-in-a-dish; help identify new treatment strategy